Dr. Leslie C. Norins brings to Analizir over 40 years of experience in medical and scientific newsletter publishing. Beginning as a one-person startup on his kitchen table, he grew several publishing companies sequentially, served as their CEO, and conceived and successfully developed national monthly periodicals on over 80 topics, serving over a million healthcare professionals, hospitals and clinics.
His companies created more than 200 jobs, many in editorial and marketing. A majority of his staffs were women. In one of his firms, he mentored the talented receptionist as she steadily progressed to become president.
Dr. Norins served on the Board of Directors of the Specialized Information Publishers Association, and was twice the keynote speaker at its national convention. He was the 2002 Inductee into the organization’s Publishers Hall of Fame. Trade publications have called him “legendary” and “the Dean of medical newsletters”. Many “alumni” of his firms have gone on to create their own publishing companies or to occupy senior editorial or marketing positions in other companies and institutions.
Dr. Norins, a native of Baltimore, received his A.B. from Johns Hopkins University, M.D. from Duke University Medical School and his Ph.D. from the University of Melbourne (Australia) where he studied immunology with the Nobel Laureate, Sir MacFarlane Burnet. He then directed a major laboratory at the federal Centers for Disease Control in Atlanta for seven years before entering the publishing phase of his career. He is a Fellow of the Infectious Disease Society of America, has published 20 scientific papers and has served on committees of the National Institutes of Health and the World Health Organization.
Robots are continually in the news for taking over many industrial tasks and causing job losses, but they have not made many inroads into creative fields. Like advertising. Automation of ad production might seem far-fetched, since advertisers customarily require
If “Facebook advertising” were a pharmaceutical, its $27 billion annual sales would dwarf those of every other available drug. But it could not be sold in the U.S. until Facebook (FB) provided the FDA with rigorous proof of efficacy?